跳到正文
原文
Endpoints News 生物医药· Ryan Cross·· 28 天前AI 评分28

Alnylam 计划扩大 RNA 药物用于亨廷顿病的临床试验

Alnylam plans bigger study of RNA drug for Huntington’s disease

AI 导读

Alnylam 计划扩大 RNA 药物用于亨廷顿病的临床试验,基于 promising 生物标志物数据。该研究旨在评估药物在患者中的疗效和安全性。

正文

As with many of the most feared neu­ro­log­i­cal con­di­tions, Hunt­ing­ton’s dis­ease has proven to be a mine­field for drug de­vel­op­ers. Promis­ing bio­mark­er da­ta

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news